Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-28T13:37:54.710Z Has data issue: false hasContentIssue false
  • English
  • Français

The effect of intranasal oxytocin application and mindfulness-based group therapy for patients with schizophrenia spectrum disorders – A study protocol

Published online by Cambridge University Press:  01 September 2022

M. Zierhut ,
V. Von Eisenhart-Rothe ,
S. Graesser ,
N. Hartter ,
J. Wohlthan ,
I. Hahne ,
N. Bergmann ,
T.M.T. Ta ,
M. Bajbouj  and
E. Hahn
...Show all authors
M. Zierhut*
Affiliation:
Charité - Univerversitätsmedizin Berlin, Campus Benjamin Franklin, Department For Psychiatry And Psychotherapie, Berlin, Germany Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Bih Academy, Clinician Scientist Program, Berlin, Germany
V. Von Eisenhart-Rothe
Affiliation:
Charité - Univerversitätsmedizin Berlin, Campus Benjamin Franklin, Department For Psychiatry And Psychotherapie, Berlin, Germany
S. Graesser
Affiliation:
Charité - Univerversitätsmedizin Berlin, Campus Benjamin Franklin, Department For Psychiatry And Psychotherapie, Berlin, Germany
N. Hartter
Affiliation:
Charité - Univerversitätsmedizin Berlin, Campus Benjamin Franklin, Department For Psychiatry And Psychotherapie, Berlin, Germany
J. Wohlthan
Affiliation:
Charité - Univerversitätsmedizin Berlin, Campus Benjamin Franklin, Department For Psychiatry And Psychotherapie, Berlin, Germany
I. Hahne
Affiliation:
Charité - Univerversitätsmedizin Berlin, Campus Benjamin Franklin, Department For Psychiatry And Psychotherapie, Berlin, Germany
N. Bergmann
Affiliation:
Charité - Univerversitätsmedizin Berlin, Campus Benjamin Franklin, Department For Psychiatry And Psychotherapie, Berlin, Germany
T.M.T. Ta
Affiliation:
Charité - Univerversitätsmedizin Berlin, Campus Benjamin Franklin, Department For Psychiatry And Psychotherapie, Berlin, Germany
M. Bajbouj
Affiliation:
Charité - Univerversitätsmedizin Berlin, Campus Benjamin Franklin, Department For Psychiatry And Psychotherapie, Berlin, Germany
E. Hahn
Affiliation:
Charité - Univerversitätsmedizin Berlin, Campus Benjamin Franklin, Department For Psychiatry And Psychotherapie, Berlin, Germany
K. Boege
Affiliation:
Charité - Univerversitätsmedizin Berlin, Campus Benjamin Franklin, Department For Psychiatry And Psychotherapie, Berlin, Germany
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Research indicates improvements in negative symptoms and empathy for schizophrenia spectrum disorders (SSD) after mindfulness-based interventions (MBI). Current treatment approaches for SSD remain limited regarding their effectiveness on negative symptoms and sociocognitive deficits. After oxytocin (OXT) administration, especially in a positive social context, an increase in empathy could be shown. The effect of mindfulness in combination with OXT has not yet been examined.

Objectives

This study investigates the additional effect of OXT administration combined with MBI on empathy and negative symptoms in patients with SSD.

Methods

An experimental, randomised, triple-blinded, placebo-controlled study is proposed. Based on power calculations, 140 participants with SSD will be recruited at Charité – Universitätsmedizin Berlin. A dose of intranasal oxytocin with 24 I.U. or placebo will be administered 45 minutes before each session. Following each administration, a total of four MBI interventions will take place for two weeks. Empathy as primary outcome will be measured using validated psychometric questionnaires. Outcomes, including negative symptoms and OXT plasma levels, will be measured at baseline and post-intervention. A 2x2 mixed-model ANCOVA design with time as within- and group as between-subject factor will be calculated to assess empathy and negative symptom changes.

Results

The study hypothesises that applying intranasal oxytocin in combination with MBI will increase empathy and reduce negative symptoms in patients with SSD.

Conclusions

Findings could provide insight into enhancing therapies like MBI by utilising OXT as a possible supplementary treatment option. Findings could therefore pave the way for a personalised psychiatric medicine treatment for individuals with SSD.

Disclosure

No significant relationships.

Keywords

MindfulnessschizophréniaOxytocinnegative symptoms
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S763
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.